Sumitomo Pharma America
55 Cambridge Parkway Suite 102W
Cambridge, MA 02142
United States
Tel: +1(508)481-6700
Website: https://www.us.sumitomo-pharma.com/
169 articles about Sumitomo Pharma America
-
This is the latest rundown of people coming and going from executive positions at biopharma companies that BioSpace covers. This regular column highlights the hired, fired, retired, promoted or resigning, as well as those personally named in lawsuits.
-
Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer
3/12/2024
Sumitomo Pharma Canada, Inc., announced that ORGOVYX®, an oral gonadotropin-releasing hormone receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced prostate cancer.
-
Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting
12/11/2023
Sumitomo Pharma America, Inc. (SMPA) today announced new data from the ongoing Phase 1/2 first-in-human study of DSP-5336, in patients with relapsed or refractory acute leukemia.
-
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis
11/2/2023
Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
-
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
9/11/2023
Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced today that the Phase 3 URO-901-3005 clinical study of vibegron.
-
Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids
5/17/2023
As part of National Women’s Health Week, Evidation and Myovant Sciences Ltd., a wholly owned subsidiary of Sumitovant Biopharma Ltd. announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
-
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
3/10/2023
Sumitovant Biopharma Ltd. ("Sumitovant") and Myovant Sciences Ltd. ("Myovant") announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
1/26/2023
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
11/16/2022
Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - November 16, 2022
11/16/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
10/26/2022
Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the second quarter of fiscal year 2022 and provided other corporate updates.
-
Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
10/24/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
-
Myovant Sciences Cancels Second Quarter Earnings Conference Call
10/24/2022
Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - October 18, 2022
10/18/2022
Myovant Sciences, a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan.
-
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022
10/14/2022
Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.
-
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
10/3/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash.
-
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma's offer after Sumitovant announced plans to acquire the company.
-
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
10/2/2022
Myovant Sciences Ltd. confirmed that it has received a preliminary, non-binding proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash.
-
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - September 16, 2022
9/16/2022
Myovant Sciences announced that it approved equity awards for 7 new employees with a grant date of September 15, 2022 pursuant to Myovant’s 2020 Inducement Plan.